Cargando…
Fecal Microbial Transplantation and Its Potential Application in Cardiometabolic Syndrome
Newly revealed links between inflammation, obesity, and cardiometabolic syndrome have created opportunities to try previously unexplored therapeutic modalities in these common and life-risking disorders. One potential modulator of these complex disorders is the gut microbiome, which was described in...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587678/ https://www.ncbi.nlm.nih.gov/pubmed/31258528 http://dx.doi.org/10.3389/fimmu.2019.01341 |
_version_ | 1783429117371219968 |
---|---|
author | Leshem, Avner Horesh, Nir Elinav, Eran |
author_facet | Leshem, Avner Horesh, Nir Elinav, Eran |
author_sort | Leshem, Avner |
collection | PubMed |
description | Newly revealed links between inflammation, obesity, and cardiometabolic syndrome have created opportunities to try previously unexplored therapeutic modalities in these common and life-risking disorders. One potential modulator of these complex disorders is the gut microbiome, which was described in recent years to be altered in patients suffering from features of cardiometabolic syndrome and to transmit cardiometabolic phenotypes upon transfer into germ-free mice. As a result, there is great interest in developing new modalities targeting the altered commensal bacteria as a means of treatment for cardiometabolic syndrome. Fecal microbiota transplantation (FMT) is one such modality in which a disease-associated microbiome is replaced by a healthy microbiome configuration. So far clinical use of FMT has been overwhelmingly successful in recurrent Clostridium difficile infection and is being extensively studied in other microbiome-associated pathologies such as cardiometabolic syndrome. This review will focus on the rationale, promises and challenges in FMT utilization in human disease. In particular, it will overview the role of the gut microbiota in cardiometabolic syndrome and the rationale, experience, and prospects of utilizing FMT treatment as a potential preventive and curative treatment of metabolic human disease. |
format | Online Article Text |
id | pubmed-6587678 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65876782019-06-28 Fecal Microbial Transplantation and Its Potential Application in Cardiometabolic Syndrome Leshem, Avner Horesh, Nir Elinav, Eran Front Immunol Immunology Newly revealed links between inflammation, obesity, and cardiometabolic syndrome have created opportunities to try previously unexplored therapeutic modalities in these common and life-risking disorders. One potential modulator of these complex disorders is the gut microbiome, which was described in recent years to be altered in patients suffering from features of cardiometabolic syndrome and to transmit cardiometabolic phenotypes upon transfer into germ-free mice. As a result, there is great interest in developing new modalities targeting the altered commensal bacteria as a means of treatment for cardiometabolic syndrome. Fecal microbiota transplantation (FMT) is one such modality in which a disease-associated microbiome is replaced by a healthy microbiome configuration. So far clinical use of FMT has been overwhelmingly successful in recurrent Clostridium difficile infection and is being extensively studied in other microbiome-associated pathologies such as cardiometabolic syndrome. This review will focus on the rationale, promises and challenges in FMT utilization in human disease. In particular, it will overview the role of the gut microbiota in cardiometabolic syndrome and the rationale, experience, and prospects of utilizing FMT treatment as a potential preventive and curative treatment of metabolic human disease. Frontiers Media S.A. 2019-06-14 /pmc/articles/PMC6587678/ /pubmed/31258528 http://dx.doi.org/10.3389/fimmu.2019.01341 Text en Copyright © 2019 Leshem, Horesh and Elinav. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Leshem, Avner Horesh, Nir Elinav, Eran Fecal Microbial Transplantation and Its Potential Application in Cardiometabolic Syndrome |
title | Fecal Microbial Transplantation and Its Potential Application in Cardiometabolic Syndrome |
title_full | Fecal Microbial Transplantation and Its Potential Application in Cardiometabolic Syndrome |
title_fullStr | Fecal Microbial Transplantation and Its Potential Application in Cardiometabolic Syndrome |
title_full_unstemmed | Fecal Microbial Transplantation and Its Potential Application in Cardiometabolic Syndrome |
title_short | Fecal Microbial Transplantation and Its Potential Application in Cardiometabolic Syndrome |
title_sort | fecal microbial transplantation and its potential application in cardiometabolic syndrome |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587678/ https://www.ncbi.nlm.nih.gov/pubmed/31258528 http://dx.doi.org/10.3389/fimmu.2019.01341 |
work_keys_str_mv | AT leshemavner fecalmicrobialtransplantationanditspotentialapplicationincardiometabolicsyndrome AT horeshnir fecalmicrobialtransplantationanditspotentialapplicationincardiometabolicsyndrome AT elinaveran fecalmicrobialtransplantationanditspotentialapplicationincardiometabolicsyndrome |